Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication Expenses
Authors' conclusion
Advancements in type 2 diabetes management have led to reduced risk of both diabetes-related outcomes and treatment harms, while maintaining relatively stable per-patient medication expenses. Although these trends are multifactorial, they suggest more rational pharmacotherapy. Still, increased risk of certain adverse events, along with increasing costs for glucose-lowering medications, underscores the need for ongoing vigilance and risk-benefit analysis.
Study context
- Population
- Danish population with T2D, 2002–2020
- Participants
- 461,805 participants
- Exposure
- Trends from 2002 to 2020
- Outcome
- Trends in balance of treatment benefits (mortality, diabetes-related outcomes) vs adverse events and medication costs
- Follow-up
- 2002 to 2020
Methodological detailsmultivariate analyses adjusted for age, sex and socioeconomic status
- Multivariate analyses adjusted for age, sex and socioeconomic status
Main finding
As reported in the abstract
Average per-patient cost reduced
8%
Total medication expenses increased (expanding population, lowered costs of most cardiovascular medications, increasing costs for glucose-lowering drugs)
148%
Median age increased
66 to 68 years
Mean number of comorbidities increased
5.2 to 8.8
Observational data: associations, not effects.
Safety
Adverse events · 2002 to 2020
- Rate of some adverse events (gastric bleeding, hypoglycemia, falls) declined
- Incidence of electrolyte imbalances and ketoacidosis increased
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →